VisceralpreADIpocytes,differentiatedandstainedwithAdipoRed™Assayreagent.
ProductOverview:
Poietics™NormalHumanPreadipocytes(HprAD)areisolatedfromsubcutaneousorvisceralfatfromnormal(non-diabetic)donors.Preadipocytesfrom diabeticdonorsareavailableasaseparateproduct.Pertinentadditionaldonorinformation,includingBodyMassIndex(BMI)maybeavailablebycontactingScientificSupport.
CryopreservedPoietics™NormalHumanPreadipocytes(HprAD)areguaranteedtocontain≥1millionor≥4million(subcutaneousonly)cellsperampouleandtestpositiveforAdipogenicdifferentiation.Allcellstestnegativeformycoplasma,bacteria,yeast,andfungi.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.
RecommendedMedium: PGM™-2PreadipocyteGrowthMedium-2BulletKit™Medium(providesbothaproliferationmediumandadifferentiationmediumguaranteedtoinducedifferentiationintomature,functionallyactiveadipocytes;EachbottleofthePGM-2™BulletKit™Mediumcontainsenoughdifferentiationmediumtofullydifferentiate10millionpreadipocytes[10complete96-wellplates]intomature,functionallyactiveadipocytes).
ThePGM™-2MediumisofferedasaBulletKit™Medium(catalogno.PT-8002)whichincludesboththebasalmediumandthenecessarysupplementsforbothproliferationanddifferentiationofpreadipocytes.Thebasalmedium(PGM™-2BasalMedium;catalogno.PT-8202)andthenecessarysupplements(PGM™-2SingleQuot™Kit;catalogno.PT-9502)canalsobepurchasedindividually.
LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.
龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach,公司经营范围包括:生物技术开发服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术推广服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术咨询、交流服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术转让服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);医学研究和试验发展(人体干细胞、基因诊断与治疗技术除外);药品研发(人体干细胞、基因诊断与治疗技术除外);货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易(涉及外资准入特别管理规定和许可审批的商品除外);生物药品制造;化学药品原料药制造;化学药品制剂制造等。